Doseage: Mild anxiety, 2-3mg daily in divided doses. Moderate to severe anxiety, 3-7mg daily in divided doses. In all patients dosage should be increased until optimal control of symptoms is achieved.

Presentation: ATIVAN is presented as blue oblong tablets each containing 1mg lorazepam and as yellow tablets containing 2.5mg lorazepam. (Also available in injectable form.)

Uses: Mild, moderate and severe anxiety.

Contraindication: Patients sensitive to benzodiazepines.

Side effects: ATIVAN is well tolerated and imbalance or ataxia is an indication of excessive dosage. Daytime somnolence may be seen initially and is to be anticipated in the effective treatment of anxiety. It will normally diminish rapidly and may be minimised in the early days of treatment by taking the larger proportion of the daily dose before retiring. Occasional confusion, hangover, headache or nausea have also been reported.

Precautions: As with other drugs of this type, patients should be advised that their reactions may be modified (as in handling machinery, driving etc.) depending on the individual patient’s response. Tolerance to alcohol may be diminished and its consumption should be avoided. As the action of centrally acting drugs, such as phenothiazines, may be intensified, the co-prescription of these drugs should be carefully monitored as reduced dosage may be indicated. Elderly patients, or those suffering from cerebrovascular changes such as arteriosclerosis are likely to respond to smaller doses. Prolonged or excessive use of benzodiazepines may occasionally result in the development of some psychological dependence with withdrawal symptoms on sudden discontinuation. Treatment in these cases should be withdrawn gradually. Careful usage is needed in the development of dependence. ATIVAN tablets should not be administered during pregnancy unless in the judgement of the physician such administration is clinically justifiable. Special care should be taken in the first three months of pregnancy.

Legal category: POM.

Product Licence Numbers: PLO011/0034 (1mg) PLO011/0036 (2.5mg) Injection PLO011/0081.

Pack size-H.S. pack 1mg x 100; 1.5mg x 50; 2.5mg x 100; 3.2mg.

Hospital Price As per local contract.

Wyeth Laboratories, John Wyeth & Brother Ltd. Taplow, Maidenhead, Berks.

*Trade Mark
Ventolin
(salbutamol BP)

bronchodilator therapy
no asthmatic
need be without

Primary therapy
in reversible airways obstruction

Proven efficacy and β₂-selectivity

Long-acting
yet with a rapid onset of action

Protects against
exercise induced asthma

Microgram dosage
avoids systemic side effects

Available as a metered-dose aerosol
and Rotacaps with Rotahaler

VENTOLIN
PRESCRIBING INFORMATION
Uses
Relief of acute, chronic, and intermittent asthma, particularly when symptoms are sudden and unexpected. It is indicated in cases of status asthmaticus. It is not a substitute for parenteral therapy in severe acute asthma attacks. It can be used in conjunction with other bronchodilators, corticosteroids, and epinephrine. For maintenance therapy, it is recommended that once-daily treatment be given in the evening. The usual dosage is 1 inhalation 3 times per day for adults and 1 inhalation 4 times per day for children. For severe asthma, it can be administered more frequently, up to every 2 hours, but not continuously. For maintenance therapy, it is recommended that once-daily treatment be given in the evening. The usual dosage is 1 inhalation 3 times per day for adults and 1 inhalation 4 times per day for children. For severe asthma, it can be administered more frequently, up to every 2 hours, but not continuously.

Dosage and administration
As with any bronchodilator, this product should be used at the discretion of the physician and the patient. It should be used when symptoms occur and not as a routine prophylactic agent. It should be used in conjunction with other medications, such as corticosteroids and beta blockers, to achieve optimal control of asthma.

Using Ventolin Inhalation
Adults: 1 inhalation every 3 hours or 1 inhalation every 4 hours.
Children: 1 inhalation every 3 hours or 1 inhalation every 4 hours.

Using Ventolin Rotahaler
Adults: 1 inhalation every 3 hours or 1 inhalation every 4 hours.
Children: 1 inhalation every 3 hours or 1 inhalation every 4 hours.

Precautions
This medication should be used with caution in patients with a history of heart disease, hypertension, or diabetes. It should be used with caution in patients with a history of severe asthma or chronic obstructive pulmonary disease. It should be used with caution in patients with a history of severe allergic reactions, including anaphylaxis.

Contraindications
This medication should not be used in patients with a history of hypersensitivity to salbutamol or any of its components. It should not be used in patients with a history of psychosis or mania.

Side effects
The most common side effects of this medication include tremor, nervousness, palpitations, and increased heart rate. Other side effects include headache, dizziness, and increased sweating.

Overdosage
Overdosage of this medication can cause severe side effects, including severe tachycardia, arrhythmias, and cardiac arrest. In case of overdose, medical attention should be sought immediately.

Drug interactions
This medication can interact with other medications, such as antidepressants, antihistamines, and beta blockers. It can also interact with other medications, such as beta blockers and antihistamines.

Product information
For further information, please refer to the product information sheet supplied with the product.

Packaging and storage
Store at room temperature. Protect from light and moisture.

Dosage and administration
As with any bronchodilator, this product should be used at the discretion of the physician and the patient. It should be used when symptoms occur and not as a routine prophylactic agent. It should be used in conjunction with other medications, such as corticosteroids and beta blockers, to achieve optimal control of asthma.

Using Ventolin Inhalation
Adults: 1 inhalation every 3 hours or 1 inhalation every 4 hours.
Children: 1 inhalation every 3 hours or 1 inhalation every 4 hours.

Using Ventolin Rotahaler
Adults: 1 inhalation every 3 hours or 1 inhalation every 4 hours.
Children: 1 inhalation every 3 hours or 1 inhalation every 4 hours.

Precautions
This medication should be used with caution in patients with a history of heart disease, hypertension, or diabetes. It should be used with caution in patients with a history of severe asthma or chronic obstructive pulmonary disease. It should be used with caution in patients with a history of severe allergic reactions, including anaphylaxis.

Contraindications
This medication should not be used in patients with a history of hypersensitivity to salbutamol or any of its components. It should not be used in patients with a history of psychosis or mania.

Side effects
The most common side effects of this medication include tremor, nervousness, palpitations, and increased heart rate. Other side effects include headache, dizziness, and increased sweating.

Overdosage
Overdosage of this medication can cause severe side effects, including severe tachycardia, arrhythmias, and cardiac arrest. In case of overdose, medical attention should be sought immediately.

Drug interactions
This medication can interact with other medications, such as antidepressants, antihistamines, and beta blockers. It can also interact with other medications, such as beta blockers and antihistamines.

Product information
For further information, please refer to the product information sheet supplied with the product.

Packaging and storage
Store at room temperature. Protect from light and moisture.

Dosage and administration
As with any bronchodilator, this product should be used at the discretion of the physician and the patient. It should be used when symptoms occur and not as a routine prophylactic agent. It should be used in conjunction with other medications, such as corticosteroids and beta blockers, to achieve optimal control of asthma.

Using Ventolin Inhalation
Adults: 1 inhalation every 3 hours or 1 inhalation every 4 hours.
Children: 1 inhalation every 3 hours or 1 inhalation every 4 hours.

Using Ventolin Rotahaler
Adults: 1 inhalation every 3 hours or 1 inhalation every 4 hours.
Children: 1 inhalation every 3 hours or 1 inhalation every 4 hours.

Precautions
This medication should be used with caution in patients with a history of heart disease, hypertension, or diabetes. It should be used with caution in patients with a history of severe asthma or chronic obstructive pulmonary disease. It should be used with caution in patients with a history of severe allergic reactions, including anaphylaxis.

Contraindications
This medication should not be used in patients with a history of hypersensitivity to salbutamol or any of its components. It should not be used in patients with a history of psychosis or mania.

Side effects
The most common side effects of this medication include tremor, nervousness, palpitations, and increased heart rate. Other side effects include headache, dizziness, and increased sweating.

Overdosage
Overdosage of this medication can cause severe side effects, including severe tachycardia, arrhythmias, and cardiac arrest. In case of overdose, medical attention should be sought immediately.

Drug interactions
This medication can interact with other medications, such as antidepressants, antihistamines, and beta blockers. It can also interact with other medications, such as beta blockers and antihistamines.

Product information
For further information, please refer to the product information sheet supplied with the product.

Packaging and storage
Store at room temperature. Protect from light and moisture.

Dosage and administration
As with any bronchodilator, this product should be used at the discretion of the physician and the patient. It should be used when symptoms occur and not as a routine prophylactic agent. It should be used in conjunction with other medications, such as corticosteroids and beta blockers, to achieve optimal control of asthma.

Using Ventolin Inhalation
Adults: 1 inhalation every 3 hours or 1 inhalation every 4 hours.
Children: 1 inhalation every 3 hours or 1 inhalation every 4 hours.

Using Ventolin Rotahaler
Adults: 1 inhalation every 3 hours or 1 inhalation every 4 hours.
Children: 1 inhalation every 3 hours or 1 inhalation every 4 hours.

Precautions
This medication should be used with caution in patients with a history of heart disease, hypertension, or diabetes. It should be used with caution in patients with a history of severe asthma or chronic obstructive pulmonary disease. It should be used with caution in patients with a history of severe allergic reactions, including anaphylaxis.

Contraindications
This medication should not be used in patients with a history of hypersensitivity to salbutamol or any of its components. It should not be used in patients with a history of psychosis or mania.

Side effects
The most common side effects of this medication include tremor, nervousness, palpitations, and increased heart rate. Other side effects include headache, dizziness, and increased sweating.

Overdosage
Overdosage of this medication can cause severe side effects, including severe tachycardia, arrhythmias, and cardiac arrest. In case of overdose, medical attention should be sought immediately.

Drug interactions
This medication can interact with other medications, such as antidepressants, antihistamines, and beta blockers. It can also interact with other medications, such as beta blockers and antihistamines.

Product information
For further information, please refer to the product information sheet supplied with the product.

Packaging and storage
Store at room temperature. Protect from light and moisture.
Becotide (becloethasone dipropionate BP)

Controls the inflammatory processes in more severe asthma

Avoids the side effects associated with systemic steroids

Can eliminate or greatly reduce the need for systemic steroids

Restores the response to bronchodilators

Obviates cushingoid features and stunting of growth in children

Available as a metered-dose aerosol and Rotacaps with Rotahaler

Using Becotide Inhaler

- Adults: two inhalations three or four times a day if the usual maintenance dose. The dosage may be increased to four inhalations per day and subsequently reduced to a minimum of two inhalations per day as required.

- Children: in most children, an initial dose of one inhalation every four hours is adequate. The dose is then increased to two inhalations every four hours as required.

Using Becotide Rotahaler

- The standard dose for adults is 250mcg every four hours.

Contra-indications

- Pregnancy, breast-feeding, and children under 12 years of age.

- Beclomethasone dipropionate is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.

- Bectotide is a potent anti-inflammatory and anti-edematous agent. It is used in the treatment of asthma and chronic obstructive pulmonary disease.
Uncomplicating hypertension

Trandate offers a unique means of controlling hypertension by combining the benefits of both beta-blockade and peripheral vasodilatation in just one drug. Suitable for all grades of hypertension, control can usually be achieved with Trandate alone simply by increasing the dose.

With a low incidence of side effects, Trandate provides simple and logical therapy avoiding the complexities of multi-drug regimens or fixed-dose combination products. Trandate uncomplicates hypertension for both doctor and patient.

Trandate labetalol hydrochloride
Dual action, singular efficacy.
Balancing the pain scale

Paramol 118
(paracetamol BP, dihydrocodeine tartrate BP)

DF 118
(dihydrocodeine tartrate BP)

If pain always stays at 100% and you're not sure how to manage it, consider using Paramol 118.

If pain is mild to moderate and you need something stronger, DF 118 is a good option.
VOCAATIONAL TRAINING FOR GENERAL PRACTICE
Devon Area Health Authority/University of Exeter
Exeter Health Care District

Applications are now invited for four places starting on 1 October 1981 for the vocational training scheme of the Department of General Practice in the Postgraduate Medical School of the University of Exeter. The course is designed and recognized for the MRCGP examination.

The four fixed programmes available are:

E. General Practice (3 months)
   Medicine and Dermatology (6 months)
   Medicine in the Community (6 months)
   Accident and Emergency (6 months)
   Obstetrics (6 months)
   General Practice (9 months)

F. General Practice (3 months)
   Obstetrics (6 months)
   Medicine and Dermatology (6 months)
   Medicine in the Community (6 months)
   Accident and Emergency (6 months)
   General Practice (9 months)

G. General Practice (3 months)
   Accident and Emergency (6 months)
   Obstetrics (6 months)
   Medicine and Dermatology (6 months)
   Medicine in the Community (6 months)
   General Practice (9 months)

H. General Practice (3 months)
   Medicine in the Community (6 months)
   Accident and Emergency (6 months)
   Obstetrics (6 months)
   Medicine and Dermatology (6 months)
   General Practice (9 months)

Throughout the three years a half-day release course is held: trainees participate actively in the planning of the course and there is emphasis on small-group work. Additional courses are available for trainees and include an introductory course for each intake, an intensive MRCGP course, and a course on management in general practice. Trainees are encouraged to carry out research work during their course and seven articles have already been published by Exeter trainees.

The Marwood Prize and the Syntex award are open to Exeter trainees annually.

The Department's prospectus is available on request and the principles underlying the teaching have been published as OCCASIONAL PAPER 4 — A SYSTEM OF TRAINING FOR GENERAL PRACTICE (available from The Royal College of General Practitioners, 14 Princes Gate, London SW7 1PU). The Department's practice management course has been expanded into a book, RUNNING A PRACTICE, published by Croom Helm, London.

This is the only University Department of General Practice in a Postgraduate Medical School in the British Isles.

Applications and enquiries should be made by 20 February 1981.

Dr D. J. Pereira Grey FRCGP
Department of General Practice
Postgraduate Medical Centre
Barrack Road
Exeter, Devon EX2 5DW
Telephone: Exeter (0392) 31159
THE MSD FOUNDATION

Audiovisual Programmes for General Practitioner Training

The MSD Foundation was set up in 1978 as an independent charity to provide videotape and tape/slide programmes for use in vocational training for general practitioners. In its first year of programme production the Foundation planned and produced a dozen programmes which are now used in day-release courses in the United Kingdom.

During 1981 the MSD Foundation plans to release a further dozen programmes covering other aspects of general practice education. Programmes available from February include:

- The Use of Medical Records in the Consultation
- The case of Darren Cooper — videotape (see below)
- Upper Respiratory Tract Infection in Children — a tape/slide programme
- The Patient Dying at Home — a dramatized video-case study in several scenes
- Immunization — a tape/slide programme
- Running a Child Development Clinic — videotape
- Safer Prescribing — tape/slide programme
- Techniques of the Consultation — the first three programmes in a structured series, analysing the consultation into specific tasks and using extracts to compare how different doctors approach these tasks
- The Management of the Arthritic Patient — a videotape programme in two parts on the diagnosis and long-term management of the arthritides in general practice

PROGRAMME OF THE MONTH

This programme might well be called:

THE CHILD AS THE PRESENTING SYMPTOM OF ILLNESS IN A PARENT — THE CASE OF DARREN COOPER

(A videotape in several scenes, duration 21 minutes)

We showed this programme to Dr Stuart Carne, FRCP, a course organizer in the NE Thames region, and here are his comments:

"The child who is not eating as much as his mother expects is a common problem. Darren is brought to his doctor by his mother because "he is not growing as much as he should do and he seems to be underweight. He doesn't eat as much as he should and never finishes a meal." Almost in parentheses the mother adds that her sister's son has coeliac disease. Could Darren be affected?

"We follow the history and are given a summary of the clinical findings. Both Darren's height and weight are on the tenth percentile. Is he also perhaps anaemic? Investigation by the general practitioner and referral to a specialist follow, but is the mother satisfied? How far does this approach solve Darren's problem — or help the general practitioner? Is the problem not with Darren but with the mother?

"Two different approaches to the management are illustrated and the viewers are invited at each stage to debate the way they would handle such a family problem.

"This videotape presentation of a case problem is suitable for both trainee and trainer discussion groups."

The Foundation has already available programmes on the following topics:

- Chronic Disease in General Practice — tape/slide programmes on asthma and hypertension
- Practice Management and Administration — tape/slide programmes in cartoon format on patient complaints and service committee procedure, how not to hire and fire a receptionist and choosing a partnership
- Video Case Studies — dramatized case histories for group discussion (management of a patient after myocardial infarction, problems at the menopause, the angry patient)
- The Consultation in General Practice — selected real consultations recorded on videotape in general practitioner surgeries around the UK. The consultations are selected because they provide a range of learning situations covering such topics as the doctor-patient relationship, techniques of the consultation, the interaction of psychological and physical illness, nonverbal behaviour and medical records

MSD Foundation programmes are sold at a price that reflects only the cost of materials. Videocassettes, available on VHS, U-Matic, Philips or Betamax cost about £20 to £25.

Further information about these programmes, including catalogues and order forms, can be obtained from The Director, The MSD Foundation, Tavistock House, Tavistock Square, London WC1. Tel: 01-387 6881.
UNIVERSITY OF BIRMINGHAM
BOARD OF GRADUATE CLINICAL STUDIES
Course Organizers Residential
Five-day Workshop
1981 March 22 to 27
at Warwick University, Coventry

A need for a National Course Organizers Workshop has been evident since the Nuffield Course ended three years ago. The West Midlands Advisers have decided to organize a week's Residential Workshop which will concentrate on management and organizational skills; educational knowledge and skills necessary for design, planning and running of half-day release courses; analysis of interviewing skills, particularly using closed-circuit television; and identifying the value of educational technology.

The Workshop is approved under Section 63 provisions and will be limited to 24 members.

Application for places should be made as soon as possible to Mrs Cathy Hunt, Secretary to The Regional Adviser, West Midlands Regional Health Authority, 146 Hagley Road, Birmingham 16.

---

SOMERSET GROUP
of six principally seeks young graduate of British university as replacement for retiring partner, to commence 1 October 1981. Privately owned, purpose built premises, full ancillary staff including practice nurse and counsellor.

Applications to include full curriculum vitae to Box No. 18.

---

CLWYD HEALTH AUTHORITY: NORTH DISTRICT
NORTH WALES
TRAINING FOR GENERAL PRACTICE

Four places on three-year training scheme for general practice starting 1 August 1981. Recognized by JCPT.

Two years in variety of hospital departments, one year in general practice. SHO grade.

Full description of scheme and application form from District Administrator, Clwyd Health Authority, North District, Rhianfa, 83 Russell Road, Rhyl. Returnable by 27 February 1981.

---

University of Bristol
Departments of Mental Health and
Extra-Mural Studies

PSYCHOTHERAPY WORKSHOP
10-15 May 1981

This workshop is intended for psychologists, psychiatrists, social workers, and general practitioners who have a few years’ experience of psychotherapy and possibly (but not necessarily) some training.

£135.50 resident membership.

Further particulars and application forms from: The Assistant Director, Department of Extra-Mural Studies (PW2), University of Bristol, 32 Tyndall's Park Road, Bristol BS8 1HR. (Telephone Bristol 24161 Ext. 196).

---

THE MEASUREMENT
OF THE QUALITY OF
GENERAL PRACTICE CARE
Occasional Paper 15

The race to measure the quality of care in general practice is on, and the promotion of quality is one of the main objectives of the Royal College of General Practitioners. Nevertheless, for many years the identification of criteria of quality has proved elusive.

Occasional Paper 15 is a detailed review of the literature by Dr C. J. Watkins, one of the senior lecturers in general practice at St Thomas’ Hospital Medical School, and forms part of the work for which he was subsequently awarded a Ph.D. It is therefore essential reading for those who are studying this fascinating subject.

The Measurement of the Quality of General Practitioner Care, Occasional Paper 15, is available now from the Royal College of General Practitioners, 14 Princes Gate, Hyde Park, London SW7 1PU, price £3.00 including postage. Payment should be made with order.
Somebody has prescribed
20,000,000
tubes of fucidin...

is it
YOU?

In boils, dirty wounds, impetigo and most other
soft tissue bacterial infections—Fucidin works.

Topical Fucidin is available as Fucidin Gel,
Fucidin H Gel, Fucidin H Ointment, Fucidin Tulle
and Fucidin Caviject... and of course

fucidin

Sodium Fusidate B.P.
Full prescribing information available from

Leo Laboratories Limited
Longwick Road, Princes Risborough,
Aylesbury, Bucks HP17 9RR.

Topical Fucidin 2% Fucidin, also available with 1% hydrocortisone. Indications Gram-positive skin infections.
Hydrocortisone preparations for inflammatory dermatoses. Contra Indications/Precautions Infections due to
non-susceptible organisms. Fucidin hypersensitivity. Avoid extensive use of hydrocortisone in pregnancy and
infants. Do not use in or near eyes. Adverse Reactions Occasional hypersensitivity reactions.

Product Licence No: 0043/5005 Basic NHS Price: 10g £1.14